Supportive care model for patients with advanced lung cancer
Patient-centered, Optimal Integration of Survivorship and Palliative Care
This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT04900935 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and evaluate the feasibility of a new supportive care model called POISE for patients with metastatic Non-small Cell Lung Cancer (NSCLC). Participants will be randomly assigned to receive either the POISE intervention, which includes four sessions with trained palliative care clinicians, or standard care. The study will assess the impact of POISE on patients' distress, confidence in managing their cancer, and understanding of their condition through surveys and interviews. Approximately 70 patients receiving targeted therapy at Massachusetts General Hospital will be involved in this research.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or older, diagnosed with metastatic NSCLC within the last six months, and currently receiving targeted therapy.
Not a fit: Patients with urgent palliative care needs, cognitive impairments, or serious mental illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the emotional and psychological well-being of patients with advanced lung cancer.
How similar studies have performed: Other studies have shown promising results with supportive care models in cancer treatment, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * MGH Cancer Center patient * Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET) * Receiving targeted therapy * Ability to respond in English or Spanish Exclusion Criteria: * Cognitive impairment or serious mental illness that limits ability to provide informed consent * Need for urgent palliative care or hospice referral * Pregnant women * Prisoners
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Laura A Petrillo, MD — Massachusetts General Hospital
- Study coordinator: Laura A Petrillo, MD
- Email: lpetrillo2@mgh.harvard.edu
- Phone: (617) 724-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.